INTRODUCTION
The DNA replication checkpoint (DRC, also called the S phase checkpoint) is an intra-cellular signaling pathway that is activated in response to replication stress (BODDY FURUYA AND CARR 2003; CICCIA AND ELLEDGE 2010) . Various factors such as nucleotide depletion, the damage of DNA templates, or polymerase inhibitors can perturb DNA replication and generate the replication stress. The activated DRC stimulates a series of protective cellular responses that promote cell survival and prevent mutations from occurring under the stress conditions. In the absence of DRC, perturbed replication forks collapse, which leads to chromosomal DNA damage or even cell death. Defects in DRC are the known causes of genome instability, cancer or other inherited diseases (AHN et al. 2004; STRACKER et al. 2008) . Therefore, the DRC is crucial for the maintenance of genome stability and highly conserved in all eukaryotes.
The DRC signaling is initiated at perturbed replication forks by the protein kinase ATR (Ataxia telangiectasia and Rad3 related) facilitated by a few other sensor proteins that are also assembled at the chromosomal DNA associated with the forks. Activated ATR phosphorylates the mediator kinase CHK1 so that the checkpoint signal can be properly amplified and received by various cellular structures. The functional homolog of CHK1 in the fission yeast S. pombe is Cds1 although the structure of Cds1 is more closely related to mammalian CHK2 or S. cerervisiae Rad53. Similar to the DRC signaling in mammalian cells, Cds1 is activated by the sensor kinase Rad3 (ATR/Mec1) and stimulate most of the protective cellular responses in S. pombe. Although the activation mechanisms of the mediator kinases Cds1 (XU et al. 2006; CAI et al. 2009 ; XU AND KELLY 2009) and CHK1 (CHEN et al. 2000; HAN et al. 2016) have been well characterized, the mechanism by which the sensor kinases are activated under replication stress remains incompletely understood (BANDHU et al. 2014; YUE et al. 2014) . Because fission yeast is an established model for studying the cellular mechanisms that are conserved in higher eukaryotes, we have been addressing this issue by searching for new S. pombe mutants that are sensitive to the replication stress induced by hydroxyurea (HU).
HU is a small molecule drug that has been used for multiple clinical implications and has a long history of scientific interests. It is a well-established inhibitor of the enzyme ribonucleotide reductase (RNR) that catalyzes the synthesis of deoxyribonucleotides from ribonucleotides. HU specifically quenches the catalytically important tyrosyl free radical within the small subunit of RNR and thus decreases the cellular dNTP levels. Consistent with this mechanism, HU slows replication forks and arrests the cell cycle in S phase (KRAKOFF et al. 1968; EHRENBERG AND REICHARD 1972; NORDLUND AND REICHARD 2006) . Slowed forks activate the DRC to upregulate RNR and increase dNTP production, which promotes fork progression and therefore protects the forks from collapsing (ELLEDGE et al. 1992; LOPES et al. 2001; SOGO et al. 2002; HU et al. 2012) . The activated DRC also delays mitosis and suppresses late firing origins so that DNA synthesis can properly resume after HU is removed (LOPEZ-MOSQUEDA et al. 2010; ZEGERMAN AND DIFFLEY 2010) . Thus, the DRC plays a key role in cell survival in HU by preventing aberrant mitosis and DNA damage generated at collapsed forks, which are generally believed to be the direct causes of cell death in mutants with a defective DRC (SOGO et al. 2002; HU et al. 2012) . In support of this hypothesis, up-regulation of RNR small subunit, which has been observed in HU-resistant mammalian cell lines (AKERBLOM et al. 1981; CHOY et al. 1988) , suppresses the HU sensitivity of yeast DRC mutant cells. However, the mechanism by which HU kills wild type cells with a functional DRC remains less clear. Although the DNA damage generated at collapsed forks may play an important role in the cell-killing process, direct evidence is still lacking.
Recent studies have shown that HU may kill the cells by alternative mechanisms such as by generating oxidative stress (DAVIES et al. 2009 ). Here, we report the identification of a novel mutation in the erg11 gene in fission yeast, which is predicted to encode the essential enzyme sterol-14α-demethylase Erg11, a P450 enzyme in the ergosterol biosynthesis pathway (TURI AND LOPER 1992a) . The structure and the catalysis of Erg11 are highly conserved in human Cyp51 (STRUSHKEVICH et al. 2010) . Interestingly, Erg11 is also a major therapeutic target of antifungals (BECHER AND WIRSEL 2012). We found that the newly identified erg11 mutation can dramatically sensitize the cells to chronic HU treatment. Surprisingly, unlike wild type or DRC mutants, in which HU induces an S phase cell cycle arrest, HU mainly arrests the erg11 mutant cells in cytokinesis. Thus, these results clearly show that HU inhibits cell proliferation through a previously unknown mechanism. We propose that in addition to the primary target RNR, HU may have a secondary unknown target(s) inside the cells. Because HU has a long history of clinical use, understanding the novel cell-killing mechanism of HU may therefore greatly improve the HU-based chemotherapies.
MATERIALS AND METHODS

Yeast strains and plasmids
Standard methods and genetic techniques were used for the yeast cell culture (MORENO et al. 1991) . Yeast strains used in this study are listed in Table S1 . The plasmids and PCR primers are listed in Table S2 and S3, respectively. To delete the erg11 gene, XhoI and BamHI sites were generated by PCR in the open reading frame (ORF) of erg11 between 79 bp to 2568 bp from the start codon in the plasmid pYJ1519 ( Figure S3A ). After digestion with the two restriction enzymes, 2489 bp fragment was removed from pYJ1519 by agarose gel electrophoresis and replaced with ura4 marker to generate the deletion construct pYJ1526. The deletion construct was digested with BglII and PacI to isolate the 3818 bp gene replacement fragment, which was transformed into the wild type diploid strain YJ18. Colonies formed on EMM plates lacking uracil were screened by colony screen PCR to confirm the correct 5' and 3' integrations. The confirmed diploid strain was saved as YJ1245 and the essentiality of erg11 was assessed by tetrad dissection ( Figure  S3A ). A similar approach was used for integration of the erg11-1 mutation at its genomic locus in the wild type diploid strain YJ18 and subsequent tetrad dissection ( Figure   S3B ). As a control, wild type erg11 was integrated using the same method. For the experimental convenience, the ura4 marker in the erg11∆ mutant YJ1259 strain was also replaced with KanRMX6 marker and saved as YJ1298.
Identification of erg11-1 mutant Screening of new HU-sensitive (hus) mutants was carried out following a previously described method (ENOCH et al. 1992) . Briefly, the logarithmically growing wild type TK1 strain was harvested and suspended in 50 mM Tris-Maleate buffer, pH 6.0, and treated with 375 µg/ml methylnitronitrosoguanidine (MNNG) in the same buffer for 90 min at room temperature. MNNG is a potent carcinogen that alkylates genomic DNA at the O 6 of guanine and O 4 of thymine, leading to transition mutations between GC and AT. The TK1 cells were also mutagenized by treatment with 150 J/m 2 ultraviolet (UV) light (Stratalinker 2400) after the cells were filtered onto filter papers. The cells were washed twice after the mutagenesis with phosphate buffered saline (PBS), resuspended in EMM6S medium, and saved at 4˚C. For the hus screening, the mutagenized cells were spread on YE6S plates and incubated at 30˚C. The colonies were replicated onto YE6S plates containing HU to identify those that were sensitive to HU. The initially identified hus mutants were backcrossed three times to remove the by-stander mutations. The resulting hus mutants were crossed and compared with all known checkpoint mutants and the mutants that are sensitive to HU in order to identify novel hus mutants. Preliminary characterization of one of our screened mutants hus41 (XU 2016) showed that this mutant contains a novel single nucleotide change in the erg11 gene, which causes a G189D mutation in sterol 14α-demethylase (Figure 1 ). The hus41 mutant was subsequently renamed as erg11-1 mutant in this study.
Drug sensitivity
To test the drug sensitivity by spot assay, 2 x 10 7 cells/ml of logarithmically growing S. pombe were diluted in three-or five-fold steps and spotted onto YE6S plates or YE6S plates containing HU or methyl methanesulfonate (MMS) at the indicated concentrations. The cells spotted on plates were also exposed to UV light at the indicated doses. All plates were incubated at 30˚C for 3 days and then photographed. The sensitivity of S. pombe to acute HU treatment was carried out using a standard method (ENOCH et al. 1992) . Briefly, after HU was added to the culture at a final concentration of 15 mM, an aliquot of the culture was removed every hour during the drug treatment, diluted 1000 fold in sterile deionized water and spread onto YE6S plates. The plates were incubated at 30˚C for 3 days for the cells to recover. The colonies formed by the recovered cells were counted and presented as percentages relative to untreated cultures. Each data point represents the average of the numbers of colonies on three separate plates.
Western blotting
Phospho-specific antibodies against phosphorylated Mrc1-Thr 645 , Cds1-Thr 11 and Rad9-Thr 412 were generated using the chemically synthesized phosphopeptides (XU et al. 2006; XU AND KELLY 2009 ). Rad9 and Cds1 were tagged with a hemagglutinin (HA) epitope and immunoprecipitated (IPed) from whole cell lysates prepared with the glassbead method in the buffer containing 50 mM HEPES/NaOH (pH 7.6), 1 mM EDTA, 1 mM Na 3 VO 4 , 10 mM pyrophosphate, 50 mM NaF, 60 mM ß-glycerophosphate, 0.1% Nonidet P-40 and protease inhibitors. After separation by SDS PAGE, samples were transferred to a nitrocellulose membrane. The membrane was briefly probed with anti-HA antibody (Santa Cruz Biotechnology) to show the HA-tagged proteins. The blotting signal was detected by electrochemiluminescence and photographed with an Image Reader LAS-3000 (Fuji Film). Band intensities were quantitated by ImageGauge (Fuji Film). The blots were usually stripped by incubating at 70˚C for 30 min in the buffer containing 50 mM Tris:HCl (pH 7.5), 50 mM DTT and 2% SDS. After extensive washes in distilled water, the stripped blots were blocked with 5% milk and reprobed with the phospho-specific antibodies in the presence of 5% milk for 3 h at room temperature or overnight at 4˚C. Phosphorylation of Mrc1-Thr 645 was directly examined in whole cell lysates prepared by the trichloroacetic acid (TCA) method (XU et al. 2006) . The stripped membranes were probed with polyclonal antibodies against Mrc1 to assess the loading. Phosphorylation of Chk1 by Rad3 was assessed using the standard mobility-shift method (LIMBO et al. 2011) .
Flow cytometry
0.5 OD 600nm cells were collected by centrifugation and fixed in 1 ml of ice-cold 70% ethanol for ≥ 3 h or overnight at 4˚C. The fixed cells were treated with 0.1 mg/ml RNase A in 50 mM sodium citrate at 37˚C for ≥ 5 h and then stained with 4 µg/ml propidium iodide (PI). Stained cells were extensively vortexed and directly analyzed using an Accuri C6 flow cytometer. Collected data were analyzed by using FCS Express 4Flow software. The FL2-A channel was used for all histograms shown in this study.
Microscopy
The cells were fixed in 2.5% glutaraldehyde at 4˚C for ≥ 3 h. After washing with PBS by centrifugation at 2300 g for 30 sec., the fixed cells were stained in the same buffer containing 5 µg/ml of 4', 6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) and 1:100 dilution of the Blankophor working solution (1:1000 dilution of a stock solution, MP Biochemicals) for 5-10 min on ice. The stained cells were examined using an Olympus EX41 fluorescent microscope. Images were captured with an IQCAM camera (Fast1394) using Qcapture Pro 6.0 software. Individual images were extracted into Photoshop (Adobe) to generate the figures.
RESULTS
Identification of the new HU sensitive mutant erg11-1
To better understand the checkpoint signaling at perturbed replication forks, we carried out a genetic screen in S. pombe looking for novel mutants that are sensitive to the replication stress induced by HU (ENOCH et al. 1992) . After extensive crosses with all known mutants that are sensitive to HU, including all checkpoint mutants, this hus (HU sensitive) screen identified several new mutants that are highly sensitive to HU. In this paper, we report the characterization of one of our newly screened mutants that was initially described as hus41 (XU 2016) . This mutant was subsequently renamed as erg11-1 in this study after the identification of the mutation and the mutated gene (see below). Other newly screened hus mutants will be reported elsewhere.
The HU sensitivity of the initially screened hus41 mutant was examined by standard spot assay and compared with known checkpoint mutants, including rad3, cds1 and chk1 ( Figure 1, A and D) . We found that the mutant was highly sensitive to HU. The sensitivity was remarkable in that it was even slightly higher or equal to that of rad3, one of the most HU sensitive mutants known so far in S. pombe ( Figure 1D ). Because of the remarkable sensitivity, we tested the HU from two different manufacturers and from various batch numbers to verify that the cell-killing effect was caused by HU and not by impurities. All of the samples had an indistinguishable cell-killing effect ( Figure  S1 ), which shows that the remarkable cytotoxicity was indeed caused by HU.
To identify the mutation in hus41, S. pombe genomic expression libraries were made using DNA purified from the wild type strain TK1 (Table S1 ) and then transformed into the hus41 cells to screen colonies with conferred HU resistance. After screening a total of ~ 40,000 yeast colonies, 11 such HUresistant colonies were isolated. The plasmids were recovered from the isolated colonies and then subject to digestion with restriction enzymes. The digestion results showed that the recovered plasmids carried two common pieces of genomic DNA. DNA sequencing showed that either erg11 gene encoding the predicted sterol-14α-demethylase or pof1 gene encoding an F-box/WD repeat protein might be able to confer the HU resistance in hus41.
To confirm the result, we cloned the erg11 and pof1 genes from the TK1 strain and the hus41 mutant, respectively, and expressed them on a vector in the hus41 mutant cells. The results showed that while erg11 could almost fully rescue hus41 ( Figure 1A ), pof1 could not ( Figure S2 ), indicating that erg11 might be the gene that was mutated in hus41. Subsequent DNA sequencing identified a single G -> A mutation that would cause a G189D amino acid change in the Erg11 enzyme ( Figure 1B ). We also sequenced the pof1 gene cloned from the hus41 mutant, no mutation was found. Interestingly, although weaker than wild type enzyme, the mutated Erg11 expressed on the vector could also rescue hus41 ( Figure 1A ). Because the protein levels are usually higher when expressed from vectors that exist in multiple copies inside the cell, this result indicates that either the erg11 mutation is hypomorphic or an unknown mutation remains to be identified in hus41.
To distinguish between these two possibilities, we deleted erg11 in the wild type diploid strain YJ18 by replacing it with the ura4 marker ( Figure S3A ). Tetrad dissection showed that the deletion is lethal, which confirms a previous genome wide deletion study (KIM et al. 2010) . Expressing Erg11 ectopically on a vector conferred normal cell growth and HU resistance in erg11∆ haploid cells ( Figure 1C ). Interestingly, the erg11∆ cells expressing the mutated Erg11 were only slightly sensitive to HU. This result shows that the HU sensitivity was likely caused by a hypomorphic mutation in hus41 and not by an unidentified mutation. We then fused the mutated erg11 with the ura4 marker and integrated it at its genomic locus in a wild type strain ( Figure S3B ). All integrants showed the HU sensitivity similar to hus41 such as the one shown in Figure 1D . In contrast, none of the integrants of wild type erg11 obtained by using the same method were sensitive to HU ( Figure 1D ). Furthermore, the DRC signaling in the integrated mutants was almost identical to that in the hus41 cells ( Figure S4 ). To confirm the over-expression of Erg11 in cells containing an expression vector, we tagged the wild type and the mutant enzyme with a triple HA epitope at the C-terminus and expressed the tagged enzyme from the genomic locus or from a vector in the erg11∆ cells. We found that the protein level of Erg11 expressed from the vector were about 4 folds higher than that expressed from the genomic locus ( Figure S5 ). Together, we have identified a hypomorphic mutation in erg11 that dramatically sensitizes S. pombe to the clinically used drug HU. In the rest of this study, the hus41 mutant was therefore renamed as erg11-1.
The conserved function of Erg11 in sterol synthesis
Erg11 is a P450 enzyme that catalyzes the key step, lanosterol-14α-demethylation, in the biosynthesis of ergosterol, a sterol that is similar to mammalian cholesterol and specifically found in fungal cell membranes (TURI AND LOPER 1992b; ESPENSHADE AND HUGHES 2007). The structure and the catalysis of Erg11 are conserved in human Cyp51 with a subtle difference in the substrates. For this reason, it is one of the major targets of antifungal agents (BECHER AND WIRSEL 2012). It was therefore a surprise that our screen identified an erg11 mutation that dramatically sensitizes the cells to HU. The mutated glycine residue in Erg11 is absolutely conserved from yeasts to humans ( Figure 1E ). Interestingly, based on the crystal structure of human Cyp51, the mutated residue is located outside of the catalytic center, which is consistent with the hypomorphic mutation and suggests that the catalysis may not be seriously affected. Because the mutated glycine is surrounded by three negatively charged, two positively charged and two histidine residues ( Figure 1F ), it is possible that mutation to the negatively charged aspartic acid may perturb the local protein structure and thus decrease the enzymatic activity (LAMB et al. 1999) . Because all of these residues are highly conserved ( Figure 1E) , it is also possible that the same mutation in other eukaryotes may have a similar effect. To test this hypothesis, we overexpressed the S. cerevisiae Erg11 and human Cyp51 in wild type or mutant S. pombe ( Figure 1G ). The results showed that under normal conditions, overexpression of the homologous enzymes did not affect cell growth in S. pombe. Interestingly, both the S. cerevisiae and human enzymes could partially rescue the HU sensitivity of the erg11-1 cells, which suggests that the enzyme is highly conserved. We also introduced the same G to D mutation in the human and S. cerevisae enzymes and found that the mutated enzymes could also partially rescue the erg11-1 mutants ( Figure S6 ). This result is consistent with the hypomorphic mutation and further supports our notion that overexpression can overcome the partial defect of Erg11.
Reduced DRC signaling in the presence of HU
The HU sensitivity described above suggest that the mutation may cause a defect in the DRC, which subsequently leads to the cell death. We therefore examined the DRC signaling from Rad3 to Mrc1 (human Claspin) and Cds1 using Western blotting with phospho-specific antibodies (Figure 2) . We have previously shown that in the presence of HU, two TQ motifs containing Thr 645 and Thr 653 residues in Mrc1 are phosphorylated by Rad3 in S. pombe. Once phosphorylated, the two TQ motifs function redundantly in recruiting Cds1 to be phosphorylated by Rad3 (XU et al. 2006) . As shown in Figure 2A , when wild type cells were treated with HU, Thr 645 in Mrc1, a representative of the two threonine residues in the redundant TQ motifs, was highly phosphorylated. Deletion of rad3 completely eliminated the phosphorylation, which is consistent with Rad3 dependent phosphorylation (compare rad3∆ with wild type and mrc1∆ cells). In HU-treated erg11-1 cells, however, the Mrc1 phosphorylation was reduced to ~ 67% of the level in wild type cells. Interestingly, the protein level of Mrc1 was also significantly lower in the HU-treated erg11-1 cells (second panel from the top), which may provide an explanation for the reduced phosphorylation. To confirm the result, we compared the Mrc1 phosphorylation in hus41 with that in cells with the integrated erg11-1 mutation and found that the results were almost identical ( Figure S4 ). We then examined Mrc1 phosphorylation at various time points during the HU treatment ( Figure  2B ). The results clearly showed that unlike the wild type cells in which the Mrc1 level was significantly increased by HU, the Mrc1 protein remained at a low level in erg11-1 cells during the 5 h long HU treatment. Since the transcription factor Cdc10 that regulates the expression of Mrc1 is a target of DRC (IVANOVA et al. 2013) , the low Mrc1 level might be due to a checkpoint defect. Alternatively and as it is shown below, the low level of Mrc1 was likely caused indirectly by a cell cycle defect.
We next examined the phosphorylation of Rad9 in the 9-1-1 checkpoint clamp complex ( Figure 2C ). In the presence of HU, Rad3 also phosphorylates Thr 412 in Rad9 Cterminus (FURUYA et al. 2004) to facilitate the phosphorylation of Cds1. Tel1 (ATM in humans), the second sensor kinase in S. pombe, which is not required for cell survival in HU, also phosphorylates Rad9. However, double depletion of Rad3 and Tel1 completely eliminated the Rad9 phosphorylation (compare rad3∆ mutant with the rad3∆ tel1∆ double mutant). Interestingly, Rad9 phosphorylation was not affected by the erg11-1 mutation. Furthermore, in contrast to Mrc1, the protein level of Rad9 was higher in the mutant even in the absence of the HU treatment.
The major DRC mediator Cds1 in S. pombe is activated by a two-stage mechanism (XU et al. 2006; XU AND KELLY 2009; YUE et al. 2011) . In the first stage, Cds1 is recruited by phosphorylated Mrc1 to be phosphorylated by Rad3 at the Thr 11 residue. In the second stage, phosphorylated Cds1-Thr 11 promotes homodimerization of two inactive Cds1 molecules, which facilitates the autophosphorylation of Thr 328 in the kinase domain. Phosphorylation of Thr 328 directly activates Cds1. Because the phosphorylation of Cds1-Thr 11 by Rad3 primes autoactivation of the kinase, it has been used as a reliable marker for Cds1 activation (TANAKA et al. 2001; YUE et al. 2011) . As shown in Figure  2D , the phosphorylation of Cds1-Thr 11 was significantly increased in HU-treated wild type cells and the phosphorylation was dependent on Rad3. Interestingly, phosphorylation of Cds1-Thr 11 was significantly decreased in the erg11-1 mutant cells. Quantitation results showed that only ~ 10% of the phosphorylation remained in the HU-treated mutant cells ( Figure 2D, bottom) . Time course study showed that Cds1 phosphorylation remained at a low level during the 5 h long HU treatment ( Figure 2E ).
Minimal sensitivity to acute HU treatment and DNA damage
The HU sensitivity determined with the standard spot assay involves a chronic drug treatment of about three days. Because the DRC mutants are sensitive to HU under various conditions, the remarkable HU sensitivity determined by spot assay prompted us to examine whether erg11-1 mutant is also sensitive to acute HU treatment ( Figure 3A) . Surprisingly, unlike the rad3 and cds1 mutants, which died within ~ 3 h or approximately one cell cycle time after HU was added to the medium, the erg11-1 mutant was relatively insensitive during the course of HU treatment. However, unlike wild type cells that continued to grow in the presence of HU, the cell growth of erg11-1 mutant was completely suppressed.
One of the major functions of the DRC is to protect perturbed forks against collapse. Consistent with this notion, the DNA damage checkpoint (DDC) is activated in HU-treated cells that lack a functional DRC, probably due to the DNA damage caused by fork collapsing. As shown in Figure 3B , the major mediator of the DDC pathway Chk1 was highly phosphorylated in HU-treated cds1 mutant (LIMBO et al. 2011) , which suggests the presence of collapsed forks (LINDSAY et al. 1998; NOGUCHI et al. 2003) . In contrast, under similar conditions, Chk1 was only minimally phosphorylated in erg11-1 cells. These results suggest that similar to wild type cells, the HU-treated forks rarely collapse in the mutant.
We also used the standard spot assay to examine the sensitivity of erg11-1 cells to DNA damage induced by methyl methanesulfonate (MMS) or ultraviolet (UV) light ( Figure S7A ). Unlike the DDC checkpoint rad3 and chk1 mutants that are highly sensitive to MMS and UV, the erg11-1 mutant showed only a minimal sensitivity. The cds1 mutant is not very sensitive to DNA damage, consistent with its main function in the DRC, not in the DDC. We then treated the cells in liquid cultures with MMS for various time points and found that the erg11-1 mutant was only minimally sensitive ( Figure S7B ). We then examined the Chk1 activation in MMS-treated erg11-1 cells ( Figure S7C ). In the presence of MMS, Chk1 was highly phosphorylated in wild type cells and the phosphorylation absolutely required Rad3. Depletion of Cds1, the major mediator of DRC, further increased the Chk1 phosphorylation. Consistent with the minimal sensitivity to DNA damage, Chk1 phosphorylation was slightly affected in erg11-1 mutant. These results clearly showed that the erg11-1 mutant was relatively insensitive to acute HU treatment and DNA damage and that the DDC signaling remained largely intact.
The checkpoint signaling defect may not play a major role in sensitizing the erg11-1 cells to HU The results described above suggest that the defect in the activation of Mrc1 and Cds1 by Rad3 may sensitize the cells to HU. However, the insensitivity to acute HU treatment and DNA damage suggests an alternative mechanism. To further investigate, we examined whether the erg11-1 mutant could be rescued by overexpression of Suc22, the small subunit of RNR. As mentioned above, in the presence of HU, one of the major functions of the DRC is to stimulate RNR so that more dNTPs are produced for DNA synthesis. Because Suc22 is the major DRC regulation target (FERNANDEZ SARABIA et al. 1993; NESTORAS et al. 2010) , overexpression of Suc22 rescued the DRC mutants, including rad3, mrc1 and cds1 ( Figure 3C ). Interestingly, under similar conditions, overexpression of Suc22 did not rescue the erg11-1 mutant, which suggests that the reduced DRC signaling may not be the major cause of lethality in HU-treated erg11-1 cells. We also crossed the erg11-1 mutation into the known checkpoint mutants to generate double mutants and examined the sensitivity of the resulting double mutants to HU, MMS and UV ( Figure S8 ). The results showed that the erg11-1 mutation has a dominant effect over the checkpoint mutants in sensitizing the cells to HU and the DNA damage caused by MMS or UV, which is consistent with our notion that the checkpoint defect may not contribute significantly to the cell death in the erg11-1 mutant.
HU arrests the erg11-1 cells mainly in cytokinesis, not in S phase of the cell cycle
Because Mrc1 is specifically expressed during early S phase, the DRC is functional only when the cells pass the G1/S transition. Outside of the S phase, the DDC is activated in the presence of DNA damage. The checkpoint signaling defect described above, in particular, the decreased Mrc1 protein level, may be caused by an indirect cell cycle effect. In support of this hypothesis, the cell growth of the erg11-1 mutant was completely suppressed in the presence of HU ( Figure 3A) . We therefore analyzed the cell cycle progression by flow cytometry during a standard HU block and release. As shown in Figure 4A , when wild type cells were treated with 15 mM HU for 3 h, most of the cells were arrested with a 1C DNA content, which is consistent with an S phase arrest. After the cells were released into fresh medium, the cells finished the bulk of DNA synthesis within ~ 2 h and then moved onto the next cycle in ~ 2.5 h. After a 3 h release, the cell cycle returned back to normal. Although the rad3 checkpoint mutant was also arrested by HU with a 1C DNA content, the cells could not recover from the arrest after the release ( Figure 4A , middle column). Interestingly, most of the erg11-1 cells were not arrested in G1/S phase by HU. Instead, they remained at G2/M during the 3 h long HU treatment. After the HU removal, a large percentage of the cells moved onto 4C DNA content, which suggests a defect in cell separation and is inconsistent with the DRC signaling defect described above.
We then stained the cells with PI and Blankophor for DNA and cell wall/septum, respectively, and examined the cells by fluorescence microscopy ( Figure 4B ). Unlike the HU-treated wild type cells that contained only one nucleus, the majority of the rad3 cells had a septum and an unequal distribution of the genomic DNA. This so-called cut (cell untimely torn) cell phenotype is a strong indicator of a checkpoint defect (SAKA AND YANAGIDA 1993) and the likely cause of cell death of checkpoint mutants in HU (arrows in Figure 4B ). Interestingly, a large number of HU-treated erg11-1 cells contained two nuclei separated by a brightly stained septum ( Figure  4B , right panel). This result is consistent with the flow cytometry data and shows that the cells were arrested by HU in cytokinesis and not in S phase. The septation index was determined during the course of the HU block and release ( Figure 4C ). When wild type cells were treated with HU, the index went down from over 20% to ≤ 5% because the activated DRC delays mitosis. After the release, the cell cycle resumed with the septation peaking at 2.5 h after the release. In contrast, when rad3 cells were treated with HU, the index went up and continued to go up to ≥ 60% after the release. Interestingly, after HU was added to erg11-1 cells, the septation index went up immediately to over 40% and remained at this high level even after the drug was removed, which indicates that the HU mainly arrests the cells in cytokinesis in a relatively stable manor and the cytokinesis arrest appears to be a separate event unrelated to the S phase arrest.
HU induces a cytokinesis arrest at low doses
Cytokinesis is the final stage of the cell division cycle and requires the proper placement, assembly and contraction of the contractile ring, which dictates septum formation and cell separation (BATHE AND CHANG 2010; JOHNSON et al. 2012; LEE et al. 2012) . The HU-induced cytokinesis observed in erg11-1 cells is likely a new cell-killing mechanism of this clinically important drug. One concern is that the cytokinesis arrest is caused by increased membrane permeability because of a defect in sterol synthesis, although the MMS resistance described above suggests that this is unlikely. To investigate this possibility, we treated the cells with HU at a wide range of concentrations from 1.5 to 50 mM. In wild type and rad3 cells, S phase arrest became apparent only when the drug concentration reached to ≥ 6.3 mM ( Figure  5A ). Below this level, the cell cycle was not arrested. In contrast, majority of the erg11-1 cells were arrested with a 4C DNA content even at 1.5 to 3.1 mM of HU (arrows in Figure 5A ), which is much lower than the concentration required for the S phase arrest in wild type and the rad3 cells. When the drug concentration was increased to ≥ 6.3 mM, most of the erg11-1 cells were blocked with a 2C DNA content, probably because cytokinesis and DNA replication were both arrested. Further increasing the HU concentration up to 50 mM, the mutant cells remained with a 2C DNA content. Interestingly, a large number of wild type cells also arrested in 2C DNA content at 50 mM HU, which is suggestive of a G2/M arrest. However, Blankophor staining showed that these cells were not arrested in cytokinesis (data not shown).
We then examined the cells treated with low doses of HU under the microscope. Using bright field microscopy, the untreated erg11-1 cells appeared similar to the rad3 and wild type cells ( Figure 5B, 1 st column from the left). These results were confirmed by Blankophor staining (2 nd column from the left). After a 3 h treatment with 3.1 mM HU, wild type and rad3 cells were morphologically similar to the untreated cells, which confirms that HU had no noticeable effects at this concentration. However, under similar conditions, the erg11-1 cells appeared morphologically distinct from the untreated erg11-1 as well as the wild type and rad3 cells (bottom panels). Most of the cells appeared to have vacuole-like structures and an enlarged nucleus ( Figures 5B and S9) . Under the fluorescent microscope, ≥ 50% cells in the culture were found to contain a brightly stained septum, which confirms that the cytokinesis arrest was induced by HU at the concentrations where it has a minimal effect on DNA replication in both wild type and rad3 cells.
The cells containing a Blankophorstained septum were counted in HU-treated and untreated cultures ( Figure 5C ). Before HU was added, ~18% of the cells had a septum in both wild type and rad3 cells, whereas the separation index was slightly higher in erg11-1 culture. However, after the cells were treated with 1.5 to 3.1 mM HU for 3 h, the index went up to ≥ 50% in erg11-1 mutant. At these low doses, HU had little effect on wild type and rad3 cells although the index in wild type cells was slightly lower. When drug concentration was increased to ≥ 6.3 mM, the index in rad3 cells began to increase to ≥ 50% and stayed at this high level after HU concentration was further increased. Under similar conditions, the index in wild type cells went down to ≤ 2%, consistent with the DRC activation and the S phase arrest shown in Figure 4C . Interestingly, further increasing the drug concentrations to ≥ 6.3 mM decreased the index to below 40% in erg11-1 cells. We believe that the decreased septation index in presence of higher concentrations of HU is likely caused by the S phase arrest, which is consistent with the results shown in Figure 4 that the cytokinesis arrest is induced by a mechanism different from that in the S phase arrest. Together, these results clearly showed that the HUinduced cytokinesis arrest was not caused by increased membrane permeability.
The cytokinesis arrest is relatively stable
The cytokinesis arrest induced by HU at low doses may explain the dramatic sensitivity of erg11-1 to chronic HU treatment. However, a transient cell cycle arrest may not be harmful enough to cause lethality. For example, most of wild type cells can fully recover from the HU-induced S phase arrest ( Figure 3A) . We next examined whether the HU-induced cytokinesis arrest in erg11-1 cells is stable. In S. pombe, G2 is the longest phase of the cell cycle. As a result, most of the logarithmically growing haploid cells have a 2C DNA content. Because the cytokinesis arrest and the S phase block are separate events and via different mechanisms in erg11-1 mutant, we reasoned that if the cytokinesis arrest is transient, the released cells should be arrested in S phase in the presence of HU, which can be easily detected by flow cytometry as the cells with a 1C DNA content. To better arrest the cells in S phase, HU concentration was increased to 25 mM in this experiment. As shown in Figure 6B , when HU was added to wild type cells, almost all cells were arrested in S phase in ≤ 3 h. Although the DNA synthesis continued in the presence of HU, the S phase arrest remained apparent for at least 5 h after the HU was added. However, during the 8 h long HU treatment, the cells with a 1C DNA content were hardly observed in erg11-1 mutant. Interestingly, the vacuole-like structures began to appear at 0.5 h and became apparent at 1 h after HU was added ( Figure 6A ). Unlike wild type cells that were significantly elongated during the later hours of HU treatment, the length of erg11-1 cells hardly changed during the course of drug treatment. Because of the continued cell growth of wild type cells in HU and uncertainty of drug decomposition, the HU treatment was stopped at 8 h. Interestingly, unlike wild type cells that could almost fully recover in 20 h from the 8 h long HU arrest, the mutant cells could not ( Figure  6C ). This result showed that the HU-induced cytokinesis arrest is relatively stable in comparison to the S phase arrest. Longer exposures even at low doses as in the spot assay may induce irreversible arrest and lead to cell death, which likely causes the remarkable HU sensitivity.
The mutation may partially affect Cds1 activation
Since the DRC is activated only when DNA replication is perturbed, it is likely that the partial defect in Cds1 activation shown in Figure 2D is caused indirectly by a cell cycle effect because in the presence of HU, most of the mutant cells were arrested in G2/M, not in S phase ( Figure S10 , right column). Consistent with this, the Mrc1 level remained low during the HU treatment and the mutant cells were not sensitive to acute HU treatment ( Figure 2B and 3A) . To investigate this further, we crossed the erg11-1 mutation into the cdc10-129 ts mutant. As mentioned above, Cdc10 is a transcription factor required for G1/S transition and the expression of Mrc1 in S. pombe. When cultured at 36.5˚C, the cdc10-129 cells arrest in G1, which allowed the release of the arrested cells into S phase at the permissive temperature 25˚C in the presence or absence of HU (LOWNDES et al. 1992) . In this way, almost all erg11-1 cells will be arrested in S phase by HU, which excludes the indirect cell cycle effect on Cds1 activation. As shown in Figure S11A , when cdc10-129 or "wild type" cells were cultured at 36.5˚C for 4 h, majority of the cells were arrested at G1. After release at 25˚C in fresh medium, the cells returned to the cycle. After a 5 h release, the cell cycle returned back to normal. In the presence of HU, the G1 released cells were arrested in S phase for ≥ 5 h. The erg11-1 cells were also arrested at G1 by culturing at 36.5˚C and then released into S phase at 25˚C although the release appeared to be slightly slower than the "wild type" cells. In the presence of HU, however, almost all G1 released cells were arrested in S phase.
We then examined Cds1 phosphorylation at 3 h after the G1 release in the presence or absence of HU. As shown in Figure S11B , Cds1 phosphorylation in G1-released-cdc10 or "wild type" cells was significantly increased in the presence of HU although the level was slightly lower than in asynchronous cells. Under similar conditions, the phosphorylation remained low in erg11-1, suggesting that the mutation has a direct impact on Cds1 phosphorylation. We also examined Cds1 phosphorylation at various time points after the G1 release ( Figure S11C ) and found that the phosphorylation peaked at 4 h in "wild type" cells after the G1 release. However, the phosphorylation remained low in the mutant cells at all time points tested. In a separate experiment, the phosphorylation was examined at 1 h after the G1 release and the same result was obtained (data not shown). Together, this result suggests that the erg11-1 mutation may partially affect the Cds1 activation in the presence of HU. However, because most of the cells were stably arrested in cytokinesis, the reduced DRC signaling may contribute minimally to the HU-induced cell death.
All other known erg mutants in the ergosterol synthesis pathway are resistant or minimally sensitive to HU An earlier report showed that a mutation in hmg1, which encodes the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase within the sterol biosynthetic pathway, causes a mild defect in cytokinesis (FANG et al. 2009 ). This suggests that sterol deficiency may be the cause of the HUinduced cytokinesis arrest. To examine the sterol level in erg11-1, we stained the cells with the fluorescent dye filipin, a polyene antibiotic that forms a specific complex with 3-b-hydroxysterols . As shown in Figure 7A , the cell tips and septa where sterol is enriched could all be stained. Interestingly, though the erg11-1 cells were also stained, the level of staining appeared to be reduced. This result showed that, consistent with the hypomorphic mutation, the sterol level might be slightly lower in erg11-1 cells. We then examined whether other mutants in the ergosterol biosynthesis pathway, including erg6∆, erg3∆ and erg4∆, are also sensitive to HU ( Figure 7B ). To our surprise, none of the tested erg mutants except erg11-1 were highly sensitive. Interestingly, deletion of the nonessential enzyme Erg6, which functions upstream of Erg11, also mildly sensitized the cells to HU although the sensitivity was not comparable to that of erg11-1. These results suggest that some of the enzymes are functionally redundant or products of the enzymes, particularly those near the end of the biosynthesis pathway, may replace the cellular functions of ergosterol.
Enhanced sensitivity to antifungal azoles
The results described above suggest that sterol deficiency may predispose the cells to the cytokinesis arrest and thus sensitize the cells to HU. It is also possible, although less likely, that a toxic by-product is generated by the mutant enzyme that sensitizes the cells to HU. To investigate this possibility, we tested whether erg11-1 mutant could be rescued chemically by exogenously supplied ergosterol. However, after the experiment was repeated multiple times with various modifications, we found that the exogenous ergosterol could not rescue the erg11-1 mutant. Consistent with this result, an earlier report showed that unlike S. cerevisiae, S. pombe does not take up the exogenous ergosterol supplied in the medium (HUGHES et al. 2005) . Thus, this lack of ergosterol uptake may provide an explanation for our negative results in rescuing the mutant with exogenous ergosterol.
Since Erg11 is the major target of antifungal azoles, its inhibitors are commercially available. We then tested the effect of Erg11 inhibitors on the cell growth and HU sensitivity of erg11-1 mutant. We reasoned that if the HU sensitivity was caused by sterol deficiency, the mutant should be more sensitive to Erg11 inhibitors and treatment of wild type S. pombe with the inhibitors should mimic the mutant effect and thus sensitize wild type cells to HU. Standard spot assays were used to test the effects of two inhibitors Clotrimazole and Terbinafine ( Figure 7C ). We found that while wild type and checkpoint mutants such as rad3, cds1 and chk1 had a similar drug resistance, the erg11-1 cells were much more sensitive to the tested drugs. These results suggest that it is likely that the sterol deficiency, and not a toxic by-product, sensitizes the erg11-1 cells to HU. We also tested a third inhibitor Itraconazole, similar results were obtained ( Figure S12A ). Importantly, we found that at the minimal drug concentration that hardly affects the cell proliferation, Itraconazole significantly sensitized wild type S. pombe to HU ( Figure S12B ), which phenocopies the erg11-1 mutation and strongly supports our conclusion that sterol deficiency sensitizes the cells to HU.
DISCUSSION
In this paper, we show that a single G189D mutation in Erg11, an essential enzyme sterol-14α-demethylase required for ergosterol biosynthesis, significantly sensitizes S. pombe to chronic HU treatment. Unexpectedly, the mutant cells are likely not killed by perturbed DNA replication, but by a previously unknown mechanism involving cytokinesis arrest. We also provide several lines of evidence that the remarkable HU sensitivity is caused by sterol deficiency, which predisposes the cells to the cytokinesis arrest induced by HU. First, when cultured in rich medium, the mutant grows almost like the wild type cells, indicating that a minimal sterol level remains for normal cell growth. Second, the genetic data suggest that the mutation is hypomorphic, which is consistent with the location of the mutation outside of the catalytic center of the enzyme and the rescuing effect of overexpressed mutant enzyme. Third, filipin staining provides direct evidence that the sterol level remains at a detectable level. Fourth, unlike the checkpoint mutants with a wild type drug resistance, the mutant is highly sensitive to the Erg11 inhibitors. Finally, treatment of wild type S. pombe with Erg11 inhibitor Itraconazole sensitizes the cells to HU, which phenocopies the erg11-1 mutant. We believe that it is unlikely that the remarkable HU sensitivity is caused by an unknown toxin generated by the mutated enzyme. Further studies are needed to understand the exact mechanism by which sterol deficiency sensitizes S. pombe to chronic HU exposure.
Because Mrc1 is specifically expressed during S phase and a stable cytokinesis arrest is induced in the mutant cells, the low levels of Mrc1 protein and its phosphorylation are likely caused indirectly by the cell cycle defect. However, it remains unclear why Cds1 phosphorylation remains at a low level even when the cells were forced to enter the S phase in the presence of HU. It is possible that abundant ergosterol is required for efficient DRC signaling in fission yeast. Nevertheless, we believe that it is unlikely that the reduced DRC signaling contribute significantly to the HU-induced cell death in erg11-1 mutant.
HU primarily targets RNR by quenching the tyrosyl free radical required for the catalysis. Consistent with this mechanism, HU arrests proliferating cells in S phase and defects in the DRC sensitizes the cells to HU, probably by aberrant mitosis and the DNA strand breaks generated at unprotected forks. However, how HU kills wild type cells with a functional DRC is less understood. Although the DNA damage generated at HU-treated forks is believed to play an important role in the cell-killing process, recent studies suggest that HU may generate oxidative stress in E.
coli (DAVIES et al. 2009; FOTI et al. 2012 ) and in S. cerevisiae (CHANG et al. 2002; HAN et al. 2010; ROWE et al. 2012) . However, it remains unclear whether this cell-killing mechanism is conserved in all eukaryotic organisms and how this mechanism is related to the cytokinesis arrest discovered in this study. Understanding the HU-induced cytokinesis arrest may shed new light on the cytotoxicity of HU and derive new therapeutic potentials because cytokinesis has been widely exploited as an antiproliferative strategy for the development of cancer chemotherapeutics (BATHE AND CHANG 2010; LEE et al. 2012) .
Cytokinesis partitions a mother cell into two daughters at the end of each cell cycle. Failure in cytokinesis results in aneuploidy and contributes to tumorigenesis (BATHE AND CHANG 2010; LEE et al. 2012) . Since ergosterol is enriched in the septum, it is possible that its deficiency directly affects the cell separation process. Alternatively, a cytokinesis protein is targeted by HU. S. pombe offers an excellent model for dissecting the mechanisms involved in this process because conserved sets of cytokinesis proteins and pathways have been identified and functionally characterized. The septa in HUtreated erg11-1 cells are all properly positioned in the middle of the cell and all cells contain only one septum. It is likely that HU affects late stages of cytokinesis. Testing the relationship between the erg11-1 mutation and a set of late stage of cytokinesis mutants such as byr4, cdc16, dma1, and nuc2 with defects in septum resolution or cell separation may pinpoint the exact step where the arrest occurs during cytokinesis (GOULD AND SIMANIS 1997; RAJAGOPALAN et al. 2003) . It is possible that in addition to RNR, HU may have a secondary unidentified target(s) inside the cell. For example, it has been shown that in vitro, HU can inhibit carbonic anhydrase and matrix metalloproteinases (SCOZZAFAVA AND SUPURAN 2003; TEMPERINI et al. 2006) .
Understanding the new cell-killing mechanism of an established drug with multiple clinical implications is important for the development of novel chemotherapeutics. Since its first synthesis more than 150 years ago, HU has been extensively studied in both laboratories and clinics (STEVENS 1999; SPIVAK AND HASSELBALCH 2011) . It is a water soluble, well-absorbed, and highly tolerable small molecule drug that has been used to treat leukemia, solid tumors, sickle cell anemia, HIV infection, psoriasis and various other diseases. Today, it remains the staple drug in the management of sickle cell anemia and chronic myeloproliferative disorders. However, despite the strong evidence of its clinical efficacies in a wide range of disorders, its use as a reliable drug in neoplastic and non-neoplastic disorders remains limited. The main reason for this limitation is due to the side effects and incomplete understanding of the mechanism underlying the toxicities. Understanding the novel cell-killing mechanism of HU may therefore greatly improve the chemotherapies that employ HU. The newly screened hus41 mutant was rescued by erg11. Standard spot assays were used to assess the HU sensitivity of wild type, rad3, hus41 carrying an empty vector (V), and hus41 carrying the same vector expressing erg11 or mutant erg11-1 cloned from hus41. 2 x 10 7 cells/ml of logarithmically growing S. pombe were diluted in five-fold steps and spotted onto YE6S plates as the control or YE6S plates containing 5.0 mM HU. The plates were incubated at 30˚C for 3 days before they were photographed. The dye Phloxin B was added to the medium in this experiment as the indicator of cell lethality. (B) DNA sequencing of the erg11 cloned from hus41 identified a single G to A mutation that causes G189D amino acid change in the enzyme. (C) Overexpression of mutant Erg11 in cells lacking the erg11 gene generated minimal HU sensitivity as determined by standard spot assay. (D) Integration of mutant erg11-1 in the erg11 genomic locus sensitized S. pombe to HU to the same level as the hus41 mutant. The erg11-1 mutation was integrated at the genomic locus as illustrated in Figure S3 . As a control, wild type erg11 was integrated by the same method. The HU sensitivity of the resulting integrants was assessed by spot assay and compared with that of wild type, rad3, cds1, chk1 and hus41 cells. (E) The mutated glycine residue in Erg11 is conserved from yeasts to humans. Regional amino acid sequences of human CYP51, S. cerevisae and S. pombe Erg11 were aligned together using the numbering of the amino acids in human CYP51 (numbers on top). Number 218 is in bold to indicate the mutated glycine residue in hus41. The highly conserved two histidines and four charged residues surrounding the mutated glycine residue are also numbered. (F) The mutated residue is located outside the catalytic center. The crystal structure of human CYP51 is shown by POLYVIEW (POROLLO 2004) . The N-and C-terminus are marked by N and C, respectively. Also shown are cyclo-hepta-amylose cocrystalized with the N-terminus and the inhibitor Econazole that occupies the catalytic center (STRUSHKEVICH et al. 2010) . The mutated region is enlarged to show the surrounding four charged residues and the two histidines numbered in E. (G) Overexpression of human CYP51 and S. cerevisiae Erg11 in S. pombe partially rescued the erg11-1 mutant. HU sensitivity of wild type or erg11-1 mutant cells carrying an empty vector or the same vector expressing human Cyp51 or S. cerevisiae Erg11 was assessed by spot assay. Expression of the human Cyp51 and S. cerevisiae Erg11 was under the control of nmt1 promoter. (-) 15 mM HU at 30˚C for 3 h in YE6S medium. Equal number of cells was collected for preparation of the whole cell extracts as described in "Materials and Methods". After separation by SDS-PAGE, the phosphorylation of Mrc1-Thr 645 by Rad3 was examined by Western blotting using a phospho-specific antibody (upper panel). The asterisk on the left denotes a non-specific, cross-reactive material. The membrane was stripped and reprobed with the polyclonal antibodies against Mrc1 (middle panel). A section of the Ponceau S-stained membrane is shown as a loading control (bottom panel). The relative levels of phosphorylation were quantitated and are shown on the bottom. (B) Mrc1 phosphorylation was examined at the indicated time points during the course of HU treatment. (C) Rad9 was tagged with HA at the N-terminus and expressed from the endogenous locus in erg11-1 or the indicated checkpoint mutant cells. After the cells were treated with 15 mM HU at 30˚C for 3 h in YE6S medium, extracts were made from an equal number of the cells. Rad9 was IPed with anti-HA antibody from the cell extracts. After separation by SDS-PAGE, phosphorylated Rad9-Thr 412 was detected by Western blotting using the phospho-specific antibodies (upper panel). Untagged cells were used as the control for HA-specific IPs (two lanes on the left). The same membrane was striped and reprobed with the anti-HA antibody to reveal the tagged Rad9 (lower panel). Relative phosphorylation levels are shown at the bottom. (D) Cds1 was tagged with HA epitope at the C-terminus and expressed at the cds1 genomic locus in wild type, erg11-1, or cells lacking Rad3. After the cells were treated with 15 mM HU for 3 h in YE6S medium, the phosphorylation of Cds1-Thr 11 was assessed in IPed Cds1 by Western blotting (top panel). The same membrane was stripped and reprobed with anti-HA antibody to examine Cds1 (bottom panel). Phosphorylation levels in various mutants are shown on the bottom. (E) The phosphorylation of Cds1-Thr 11 was examined at the indicated time points during the course of HU treatment. (A) Sensitivity of wild type, rad3, cds1 and erg11-1 mutant cells to acute treatment with HU was examined as described in Materials and Methods. After HU was added to the cultures at 15 mM, equal amount of the culture was removed, diluted 1000 fold and spread on YE6S plates to allow the cells to recover. The colonies formed from the recovered cells were counted and presented as the percentages relative to the untreated cultures. (B) Chk1 is minimally phosphorylated in HU-treated erg11-1 mutant. Chk1 phosphorylation was assessed in cells containing the indicated mutations treated with (+) or without (-) 15 mM HU at 30˚C for 3 h. (C) Unlike the rad3, cds1 and chk1 checkpoint mutants, overexpression of the small subunit of RNR Suc22 did not rescue the erg11-1 mutant. Suc22 was expressed under the control of its own promoter from a vector carrying the LEU2 marker. V indicates an empty vector. Standard spot assay was employed for assessing the HU sensitivity. The erg11-1 cells and the cells lacking the indicated enzymes in the ergosterol synthesis pathway were tested by spot assays for HU sensitivity. (C) Sensitivity of wild type cells and the cells with indicated mutations to the Erg11 inhibitor Clotrimazole (top panels) and Terbinafine (lower panels) were examined with the standard spot assays on plates containing YE6S medium. The plates were incubated at 30˚C for three days.
